Showing 7581-7590 of 8649 results for "".
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- More Data Point to Pfizer, BioNTech Vaccine Cutting COVID-19 Transmission Rateshttps://modernod.com/news/more-data-point-to-pfizer-biontech-vaccine-cutting-covid-19-transmission-rates/2478965/Mounting real-world evidence from Israel suggests that Pfizer and BioNTech’s vaccine BNT162b2 can “dramatically” cut incidence rates of COVID-19 disease in fully vaccinated individuals, according to a joint statement issued Thursday by the companies and the Israeli Ministry of H
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- Lilly’s Bamlanivimab, Etesevimab Cut Hospitalizations, Deaths in High-Risk COVID-19 Patientshttps://modernod.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/Eli Lilly reported new phase 3 results demonstrating that the antibody cocktail containing bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with SARS-CoV-2 infection. “These positive results reinforce our
- Researchers Develop New Noninvasive Technique to Image Human Eyehttps://modernod.com/news/researchers-develop-new-noninvasive-technique-to-image-human-eye/2478947/Researchers have developed a noninvasive technique that can capture images of rod and cone photoreceptors with unprecedented detail. The advance could lead to new treatments and earlier detection for retinal diseases such as macular degeneration, according to a National Eye Institute news release
- Survey Suggests People Living With Glaucoma at Increased Risk of Sight Loss and Blindness Due to COVID-19 Pandemichttps://modernod.com/news/survey-suggests-people-living-with-glaucoma-at-increased-risk-of-sight-loss-and-blindness-due-to-covid-19-pandemic/2478946/People with glaucoma have struggled to access their healthcare treatment during the COVID-19 pandemic, putting them at risk of vision loss and blindness, according to results of a new European survey of 2,010 adults with glaucoma, including 250 UK respondents.* The survey is part of a mult
- CooperVision Introduces 2021 Best Practices Honoreeshttps://modernod.com/news/coopervision-introduces-2021-best-practices-honorees/2478943/During a year of unprecedented challenges brought on by the COVID-19 pandemic, eye care practices across the nation have adapted to meet the changing needs of their patients and find ways to not only survive, but thrive. In celebration of 10 such practices, CooperVision announced its 2021 Bes
- UK, Four Other Countries to Fast-Track Vaccines for SARS-CoV-2 Variantshttps://modernod.com/news/uk-four-other-countries-to-fast-track-vaccines-for-sars-cov-2-variants/2478939/A group of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland issued new rules Thursday aimed at speeding up the development of modified COVID-19 vaccines against emerging SAR-CoV-2 strains. The guidance, developed by the UK’s Medicines and Healthcare products
- Sight Sciences Receives FDA Clearance for Expanded Indication for OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-receives-fda-clearance-for-expanded-indication-for-omni-surgical-system/2478938/Sight Sciences announced FDA 510(k) clearance of the OMNI Surgical System for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy to reduce IOP in adult patients with primary open–angle glaucoma. Historically, the majority o
- Hydrus Microstent Now First MIGS Device With 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/Ivantis, developer of the novel Hydrus Microstent, announced the first release of 5-year follow-up data from its HORIZON pivotal trial. This milestone represents the longest continuous follow-up of a MIGS device pivotal trial. The 5-year HORIZON data demonstrated the Hydrus Microstent̵